Urolog. pro Praxi, 2007; 8(4): 158-162 [Klin Farmakol Farm. 2007;21(1):12-14]

Pharmacological treatment of overactive bladder (OAB) and urge urinary incontinence

MUDr. Aleš Vidlář, MUDr. Radovan Vrtal, doc. MUDr. Vladimír Študent Ph.D
Urologická klinika FN a LF UP v Olomouci

Overactive bladder (OAB) is a chronic distressing condition characterized by urinary urgency with or without urge incontinence (UI), usually with frequency and nocturia. It affects millions of people worldwide independent of age, sex and race. The prevalence increases with age and is relatively higher in women compared with men. The treatment of OAB is aimed at reducing of the debilitating symptoms so as to improve the overall quality of life for patients. This article gives overview about known pharmacological treatment of OAB and UI with a view to anticholinergic agents (1st line drugs).

Keywords: overactive bladder, urinary urge incontinence, pharmacological treatment

Published: September 7, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vidlář A, Vrtal R, Študent V. Pharmacological treatment of overactive bladder (OAB) and urge urinary incontinence. Urol. praxi. 2007;8(4):158-162.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower tract function: report from the standardisation sub-committeee of the International Continence Society. Neurourol and Urodyn 2002; 21 (5): 1670-1678. Go to original source... Go to PubMed...
    2. Anderson K. Pharmacological treatment of urinary incontinence. Abrams P, Cardovo L, Khoury S, Sein A. 2nd Consultation on Incontinence, Paris 2001.
    3. Anderson KE, Bengtsson B, Paulsen O Desamino-8-D-arginine vasopresin (DDAVP). Pharmacology and clinical use. Drugs of today 1988; 24: 509.
    4. Anderson KE. Alpha-adrenoreceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoreceptor antagonists. Word J Urol 2002; 19 (6): 390. Go to original source... Go to PubMed...
    5. Appell R, Sand P, Dmochowski R et al. Prospective randomised controlled trial of extended- release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: resultsof OBJECT study. Mayo Clin Proc 2001; 76 (2): 358-363. Go to original source...
    6. Artibani W. Overactive bladder: new perspectives. Eur Urol 2002; Suppl. 4 (1): 1-30. Go to original source...
    7. Berghmans L, Hendriks H, De Bie R et al. Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. BJU Int 2000; 85 (2): 254-263. Go to original source... Go to PubMed...
    8. Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patiens with spastic paraplegie: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn 1993; 12: 163. Go to original source... Go to PubMed...
    9. Castelden CM, George CF, Renwick AG et al. Imipramine - a possible alternative to current therapy for urinary incontinence in the elderly. J Urol 1981; 125: 218-221. Go to original source... Go to PubMed...
    10. Cole A, Fried F. Favorable experiences with imipramine in the treatment of neurogenic bladder. J Urol 1972; 107: 44-48. Go to original source... Go to PubMed...
    11. Collas D, Mallone - Lee J. The pharmacokinetic properties of rectal oxybutynin a possible alternative to intravesical administration. Neurourol Urodyn 1997; 16 (4): 346-347.
    12. Diokno A, Appell R, Sand P et al. Prospective, randomised, double - blind study of the efficacy and tolerabilty of the extended - release formulations of oxybutynin and tolterodine for overactive bladder. Results of the OPERA trial. Mayo Clin Proc 2003; 78 (4): 687-695. Go to original source... Go to PubMed...
    13. Milson I, Abrams P, Cardozo L et al. How widespread are the symptom sof an overactive bladder and how are they manager? A population-based prevalence study. BJU Int 2001; 87: 760-6. Go to original source... Go to PubMed...
    14. Tailor MC, Bates CP. A double blind crossover trial fo Baclofen - a new treatment for unstable bladder syndrome. Br JUrol 1979; 51: 504. Go to original source...
    15. 3rd International Consultation on Incontinence, Monaco 2005, June 25-26.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.